Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Wednesday, February 22, 2017

Stem Cell Treatment May Halt MS Disability Progression


                                                                  
  
Click here to receive MS news via e-mail

Observational study finds almost half of patients progression-free at 5 years


by Kate Kneisel 

Contributing Writer, MedPage Today
FEBRUARY 21, 2017

Autologous hematopoietic stem cell transplantation (AHSCT) was associated with long-term attenuation of disability progression in almost half of patients with aggressive, treatment-refractory multiple sclerosis (MS), researchers found.

The long-term observational study of 281 patients with predominantly progressive forms of MS found that 46% of the 239 evaluable patients were free from progression and overall survival was 93% at 5 years, Paolo Muraro, MD, of Imperial College London in England, and colleagues reported online in JAMA Neurology.



The profile of a patient who may benefit from AHSCT for treatment of aggressive MS includes being younger in age, with relapsing forms of MS, a low number of prior immunotherapies, and low or moderate but not severe level of established neurological disability, Muraro told MedPage Today.
"The study results suggest a long-term treatment effect of AHSCT and strengthen the case [presented in a 2012 position paper] for randomized controlled trials of AHSCT against standard care," he added.
Patients in the multicenter study were followed for up to 16 years (mean 6.6 years). Three-quarters of patients had progressive forms of MS, mostly secondary progressive MS (66.2%). Transplant occurred a median of 81 months after MS diagnosis; 61% of patients had received at least 2 MS treatments before transplant. Median EDSS score was 6.5.




MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No comments: